I don't think their estimate for Avenova is nearly high enough. They base the $500 mill. potential on a scenario that 24 million of the 30 million dry eye/blephoritis sufferers buying one bottle a year ($20 wholesale).
As a person in sales most of my life, I think getting 24 million people on board is too high of an expectation. Lets shoot for half of that...12 million.
Next,their conservative estimate that each patient is only buying
one bottle per year is also unrealistic in that it would be a failure if only one bottle was purchased by each patient per year.
I think it would be very realistic that the 12 million (who would be the ones that need it the most out of the 30 million) would be easily buying 4 bottles a year (assuming that they stretch the use of each bottle over a 3 month period).
12 million X $80 (4 bottles @ $20 wholesale)= Just shy of $ 1 Billion. Very doable.
If they can bridge their expenses with the aid of monetizing assets, they would be sitting pretty.
The biggest risk is the time it will take to do that. They might give away the store to make a deal just to get any kind of extra revenue.
I think it will take at least 4 years until they can be profitable with Avenova.
The drug is going to do great...financing their way to profitability is the real issue. Further dilution is looming large.
Recent NBY News
- NovaBay Pharmaceuticals Supports National Dry Eye Awareness Month with Multiple Avenova Product Promotions • Business Wire • 06/28/2024 10:50:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/14/2024 12:47:55 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/07/2024 11:30:13 AM
- NovaBay Pharmaceuticals Plan of Compliance Accepted by the NYSE American • Business Wire • 06/07/2024 10:50:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/31/2024 08:50:08 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 05/31/2024 08:43:25 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/31/2024 01:31:33 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/31/2024 01:29:26 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/31/2024 01:27:15 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/31/2024 01:24:28 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/31/2024 01:17:52 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/29/2024 09:27:32 PM
- NovaBay Pharmaceuticals Announces Approval of All Proposals at its 2024 Annual Meeting of Stockholders and Provides Other Corporate Updates • Business Wire • 05/29/2024 09:22:00 PM
- NovaBay Pharmaceuticals Launches Avenova Product Bundles for Individualized Relief from Multifactorial Dry Eye Symptoms • Business Wire • 05/13/2024 12:30:00 PM
- NovaBay Pharmaceuticals Reports First Quarter 2024 Financial Results • Business Wire • 05/09/2024 08:05:00 PM
- NovaBay Pharmaceuticals Announces Record Ordered Product Sales of Avenova-Branded Products in April through Amazon • Business Wire • 05/07/2024 12:00:00 PM
- NovaBay Pharmaceuticals to Hold 2024 First Quarter Conference Call on May 9, 2024 • Business Wire • 05/03/2024 10:50:00 AM
- NovaBay Pharmaceuticals Announces New and Enhanced Direct-to-Consumer Marketing to Efficiently Engage Customers and Drive Avenova Sales • Business Wire • 04/22/2024 10:57:00 AM
- NovaBay Pharmaceuticals Receives a NYSE American Notice Regarding Stockholder Equity • Business Wire • 04/19/2024 10:00:00 PM
- NovaBay Pharmaceuticals Reports Preliminary Eyecare and Wound Care Revenue Increased 13% for the First Quarter of 2024 on Lower Sales and Marketing Expenses • Business Wire • 04/17/2024 10:59:00 AM
- NovaBay Pharmaceuticals Reports 2023 Fourth Quarter and Full Year Financial Results • Business Wire • 03/26/2024 08:05:00 PM
- NovaBay Pharmaceuticals to Hold 2023 Fourth Quarter and Full Year Conference Call on March 26, 2024 • Business Wire • 03/25/2024 10:38:00 PM
- NovaBay Pharmaceuticals Announces Agreement to Sell its DERMAdoctor Skincare Business Segment; Announces Preliminary Financial Results for Fourth Quarter and Year Ended December 31, 2023 • Business Wire • 03/14/2024 12:00:00 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 07:52:33 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/06/2024 04:52:28 PM
FEATURED Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM